DCTHDelcath Systems, Inc.
17.14USD-0.06%Mkt Cap: 594.74M $P/E: 1714.00

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphala…

Key Statistics

Company
Market Cap594.74M $
Enterprise Value487.77M $
Revenue (TTM)95.42M $
Gross Profit73.43M $
Net Income (TTM)2.70M $
Revenue/Share2.637 USD
Last Price17.14 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees156
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN
Valuation
P/E (Trailing)1714.00
P/E (Forward)372.22
PEG1.60
EV/EBITDA-335.23
EV/Revenue5.11
P/S6.09
P/B4.79
EPS (TTM)0.01
EPS (Forward)0.04
52W Range
8.12097% of range17.42
52W High17.42 USD
52W Low8.120 USD
Profitability
Gross Margin86.16%
Oper. Margin8.22%
EBITDA Margin-1.52%
Profit Margin3.17%
ROE2.43%
ROA2.18%
Growth
Revenue Growth20.60%
Earnings Growth0.00%
Cash Flow & Leverage
Operating CF22.52M $
CapEx (TTM)1.55M $
FCF Margin18.99%
FCF Yield3.05%
Net Debt-93.44M $
Net Debt/EBITDA64.22
Balance Sheet
Debt/Equity0.01
Current Ratio9.83
Quick Ratio8.45
Book Value/Sh3.498 USD
Cash/Share2.764 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay DateDec 24, 2019
Splits
Last Split1:700
Split DateDec 24, 2019
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.00 USD
Upside (mean)+40.0%
Target Range21.00 USD32.00 USD
$21.00+40.0% to mean$32.00
# Analysts5
Ownership
Shares Out.34.70M
Float28.78M
Insiders8.09%
Institutions51.78%
Short Interest
Short Ratio7.1d
Short % Float7.95%
Short % Out.7.30%
Shares Short2.53M
Short (prev mo.)2.87M
Technical
SMA 5013.40 (+27.9%)
SMA 20010.83 (+58.2%)
Beta0.52
S&P 52W Chg18.16%
Avg Vol (30d)583.12K
Avg Vol (10d)797.49K
Technical Indicators
RSI (14)71.9
MACD1.2918
MACD Signal0.9588
MACD Hist.+0.3329
BB Upper18.89 USD
BB Middle14.26 USD
BB Lower9.634 USD
BB Width64.88%
ATR (14)0.7618 USD
Vol Ratio (20d)0.76x